Register for our free email digests:
Catalent, Inc
https://www.catalent.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Catalent, Inc
Catalent Launches Technology For Softgel Innovation
Catalent has announced the launch of a new technology, OptiGel DR, for the formulation and manufacture of delayed/enteric release softgels, offering advantages such as potentially enhancing bioavailability and reducing gastric reflux effects.
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Moderna Takes Middle Ground On Pricing With 100 Million Dose US Agreement
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Services
-
Pharmaceuticals
- OTC, Consumer
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Accucaps Industries Limited
- Catalent U.K. Swindon Zydis Limited
- Cook Pharmica LLC
- Juniper Pharmaceuticals
- Molecular Profiles Ltd.
- Columbia Laboratories, Inc.